No profile data available.
Citius Pharmaceuticals, Inc. (CTXR) is a healthcare company in the IV treatment equipment industry, based in Cranford, United States, with about 23 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$37.43 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $1.49 million. Its market capitalization was $13.71 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Citius Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $1.49 million.
$13.71 million as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include RenovoRx, Inc. (RNXT), Modular Medical, Inc. (MODD), BioCardia, Inc. (BCDA).